TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection
Open accessAbstract
HIV infection induces phenotypic and functional changes to CD8+ T cells defined by the coordinated upregulation of a series of negative checkpoint receptors that eventually result in T cell exhaustion and failure to control viral replication. We report that effector CD8+ T cells during HIV infection in blood and SIV infection in lymphoid tissue exhibit higher levels of the negative checkpoint receptor TIGIT. Increased frequencies of TIGIT+ and TIGIT+ PD-1+ CD8+ T cells correlated with parameters of HIV and SIV disease progression. TIGIT remained elevated despite viral suppression in those with either pharmacological antiretroviral control or immunologically in elite controllers. HIV and SIV-specific CD8+ T cells were dysfunctional and expressed high levels of TIGIT and PD-1. Ex-vivo single or combinational antibody blockade of TIGIT and/or PD-L1 restored viral-specific CD8+ T cell effector responses. The frequency of TIGIT+ CD4+ T cells correlated with the CD4+ T cell total HIV DNA. These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells and suggest TIGIT along with other checkpoint receptors may be novel curative HIV targets to reverse T cell exhaustion.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CD96 inhibits NK cell activity in murine cancer models.
“These include the TIM-3, LAG-3, TIGIT, and B- And T-Lymphocyte-Associated Protein (BTLA) receptors associated with T cell exhaustion as well as VISTA, a receptor found on tumor-infiltrating myeloid cells, whose inhibition promoted anti-tumor immune responses in murine models, and CD96, which has been shown to inhibit NK cell activity in murine cancer models (115–117).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [117]
VISTA inhibition promoted anti-tumor immune responses in murine models.
“These include the TIM-3, LAG-3, TIGIT, and B- And T-Lymphocyte-Associated Protein (BTLA) receptors associated with T cell exhaustion as well as VISTA, a receptor found on tumor-infiltrating myeloid cells, whose inhibition promoted anti-tumor immune responses in murine models, and CD96, which has been shown to inhibit NK cell activity in murine cancer models (115–117).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1× · see citing works
“During chronic viral infections, high antigenic loads continually stimulate T cells leading to progressive loss of function termed “T cell exhaustion” [1].”
BackgroundThe interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524 · see citing works
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680 · see citing works
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,383 · see citing works
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · see citing works
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565 · see citing works
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M. F. C., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,556 · see citing works
Yu, X., Harden, K., Gonzalez, L. C., Francesco, M. R., Chiang, E. Y., Irving, B. A., Tom, I., Ivelja, S., Refino, C. J., Clark, H. F., et al. (2008) · Nature Immunology · doi:10.1038/ni.1674 · Cited by 1,486 · see citing works
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps‐Agrar, L., Hackney, J. A., Yu, X., Huseni, M. A., Yang, Y., Park, S., Javinal, V., Chiu, H. H., Irving, B. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,191 · see citing works
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186 · see citing works
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D. M., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,145 · see citing works
Joller, N., Lozano, E., Burkett, P. R., Patel, B., Xiao, S., Zhu, C., Xia, J., Tan, T.-G., Sefik, E., Yajnik, V., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.012 · Cited by 904 · see citing works
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M. F., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 785 · see citing works
Self-citationEnhancing SIV-specific immunity in vivo by PD-1 blockade
Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L. S., Silvestri, G., Freeman, G. J., et al. (2008) · Nature · doi:10.1038/nature07662 · Cited by 765 · see citing works
Jones, R. B., Ndhlovu, L. C., Barbour, J. D., Sheth, P. M., Jha, A. R., Long, B. R., Wong, J. C. Y., Satkunarajah, M., Schweneker, M., Chapman, J. M., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081398 · Cited by 748 · see citing works
Self-citationDuraiswamy, J., Kaluza, K. M., Freeman, G. J., & Coukos, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4100 · Cited by 737 · see citing works
Shan, L., Deng, K., Shroff, N. S., Durand, C. M., Rabi, S. A., Yang, H., Zhang, H., Margolick, J. B., Blankson, J. N., & Siliciano, R. F. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.014 · Cited by 707 · see citing works
Hunt, P. W., Brenchley, J. M., Sinclair, E., McCune, J. M., Roland, M. E., Page, K. A., Hsue, P. Y., Emu, B., Krone, M., Lampiris, H. W., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/524143 · Cited by 639 · see citing works
Self-citationTACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease
Gross, J. A., Dillon, S. R., Mudri, S., Johnston, J. V., Littau, A., Roque, R., Rixon, M. W., Schou, O., Foley, K. P., Haugen, H. S., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00183-2 · Cited by 625 · see citing works
Deeks, S. G. (2012) · Nature · doi:10.1038/487439a · Cited by 606 · see citing works
Self-citationCutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Joller, N., Hafler, J. P., Brynedal, B., Kassam, N., Spoerl, S., Levin, S. D., Sharpe, A. H., & Kuchroo, V. K. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003081 · Cited by 574 · see citing works
Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513 · see citing works
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
Deng, K., Pertea, M., Rongvaux, A., Wang, L., Durand, C. M., Ghiaur, G., Lai, J., McHugh, H., Hao, H., Zhang, H., et al. (2015) · Nature · doi:10.1038/nature14053 · Cited by 499 · see citing works
Self-citationBalancing natural killer cell activation through paired receptors
Martinet, L., & Smyth, M. J. (2015) · Nature reviews. Immunology · doi:10.1038/nri3799 · Cited by 483 · see citing works
Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection
Papagno, L., Spina, C. A., Marchant, A., Salio, M., Rufer, N., Little, S., Dong, T., Chesney, G., Waters, A., Easterbrook, P., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020020 · Cited by 478 · see citing works
The TIGIT/CD226 Axis Regulates Human T Cell Function
Lozano, E., Dominguez‐Villar, M., Kuchroo, V. K., & Hafler, D. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103627 · Cited by 475 · see citing works
Younes, S., Yassine‐Diab, B., Dumont, A. R., Boulassel, M., Grossman, Z., Routy, J., & Sékaly, R. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031598 · Cited by 459 · see citing works
Lambotte, O., Boufassa, F., Madec, Y., Nguyen, A., Goujard, C., Meyer, L., Rouzioux, C., Venet, A., Delfraissy, J., & SEROCO-HEMOCO Study Group (2005) · Clinical Infectious Diseases · doi:10.1086/433188 · Cited by 407 · see citing works
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lönberg, N., Taylor, L. D., Harding, F., Trounstine, M. L., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 399 · see citing works
Wei, D. G., Chiang, V., Fyne, E., Balakrishnan, M., Barnes, T. L., Graupe, M., Hesselgesser, J., Irrinki, A., Murry, J. P., Stepan, G. J., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004071 · Cited by 272 · see citing works
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
Boles, K. S., Vermi, W., Facchetti, F., Fuchs, A. G., Wilson, T. J., Diacovo, T. G., Cella, M., & Colonna, M. (2009) · European Journal of Immunology · doi:10.1002/eji.200839116 · Cited by 269 · see citing works
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T. G., Hudson, D., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266 · see citing works
Gardiner, D., Lalezari, J. P., Lawitz, E., DiMicco, M., Ghalib, R., Reddy, K. R., Chang, K., Sulkowski, M., Marro, S. O., Anderson, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063818 · Cited by 230 · see citing works
Self-citationKaufmann, D., & Walker, B. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803771 · Cited by 229 · see citing works
Stengel, K. F., Bowles, K. H., Yu, X., Rougé, L., Yin, J., Comps‐Agrar, L., Wiesmann, C., Bazán, J. F., Eaton, D., & Grogan, J. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120606109 · Cited by 216 · see citing works
Hatano, H., Delwart, E., Norris, P. J., Lee, T., Dunn-Williams, J., Hunt, P. W., Hoh, R., Stramer, S. L., Linnen, J. M., McCune, J. M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01763-08 · Cited by 208 · see citing works
Self-citationPersistent Low‐Level Viremia in HIV‐1 Elite Controllers and Relationship to Immunologic Parameters
Pereyra, F., Palmer, S., Miura, T., Block, B. L., Wiegand, A. P., Rothchild, A. C., Baker, B. M., Rosenberg, R., Cutrell, E., Seaman, M. S., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605446 · Cited by 204 · see citing works
Yamamoto, T., Price, D. A., Casazza, J. P., Ferrari, G., Nason, M., Chattopadhyay, P. K., Roederer, M., Emma Gostick, D., Katsikis, P. D., Douek, D. C., et al. (2011) · Blood · doi:10.1182/blood-2010-11-317297 · Cited by 191 · see citing works
Comparison of HDAC inhibitors in clinical development
Rasmussen, T. A., Søgaard, O. S., Brinkmann, C. R., Wightman, F., Lewin, S. R., Melchjorsen, J., Dinarello, C. A., Østergaard, L. J., & Tolstrup, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23800 · Cited by 191 · see citing works
Epidemiology and clinical characteristics of elite controllers
Okulicz, J. F., & Lambotte, O. (2011) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328344f35e · Cited by 182 · see citing works
Petrovas, C., Price, D. A., Mattapallil, J. J., Ambrozak, D. R., Geldmacher, C., Cecchinato, V., Vaccari, M., Tryniszewska, E. A., Emma Gostick, D., Roederer, M., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069112 · Cited by 172 · see citing works
Shetty, R. D., Velu, V., Titanji, K., Bosinger, S. E., Freeman, G. J., Silvestri, G., & Amara, R. R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60612 · Cited by 156 · see citing works
Evidence for Innate Immune System Activation in HIV Type 1–Infected Elite Controllers
Krishnan, S., Wilson, E. M. P., Sheikh, V., Rupert, A. W., Mendoza, D., Yang, J., Lempicki, R. A., Migueles, S. A., & Sereti, I. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit581 · Cited by 148 · see citing works
Tian, X., Zhang, A., Qiu, C., Wang, W., Yang, Y. Z., Qiu, C., Liu, A., Zhu, L., Yuan, S., Hu, H., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402176 · Cited by 145 · see citing works
Role of PD-1 in HIV Pathogenesis and as Target for Therapy
Porichis, F., & Kaufmann, D. (2011) · Current HIV/AIDS Reports · doi:10.1007/s11904-011-0106-4 · Cited by 137 · see citing works
Crowell, T. A., Gebo, K. A., Blankson, J. N., Korthuis, P. T., Yehia, B. R., Rutstein, R. M., Moore, R. D., Sharp, V., Nijhawan, A. E., Mathews, W. C., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu809 · Cited by 129 · see citing works
Cell-associated HIV RNA: a dynamic biomarker of viral persistence
Pasternak, A. O., Lukashov, V. V., & Berkhout, B. (2013) · Retrovirology · doi:10.1186/1742-4690-10-41 · Cited by 127 · see citing works
Kumar, A. M., Borodowsky, I., Fernandez, B., Gonzalez, L. E., & Kumar, M. (2007) · Journal of NeuroVirology · doi:10.1080/13550280701327038 · Cited by 123 · see citing works
Vali, B., Jones, R. B., Sakhdari, A., Sheth, P. M., Clayton, K., Yue, F., Gyenes, G. T., Wong, D., Klein, M. B., Saeed, S., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.201040340 · Cited by 101 · see citing works
Self-citationMujib, S., Jones, R. B., Lo, C. C., Aidarus, N., Clayton, K., Sakhdari, A., Benko, E., Kovacs, C. M., & Ostrowski, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102609 · Cited by 101 · see citing works
Self-citationClayton, K., Douglas-Vail, M. B., Rahman, A. K. M. N.-U., Medcalf, K. E., Xie, I. Y., Chew, G. M., Tandon, R., Lanteri, M. C., Norris, P. J., Deeks, S. G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00006-15 · Cited by 92 · see citing works
Self-citationCD160-Associated CD8 T-Cell Functional Impairment Is Independent of PD-1 Expression
Viganó, S., Banga, R., Bellanger, F., Pellaton, C., Farina, A., Comte, D., Harari, A., & Perreau, M. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004380 · Cited by 76 · see citing works
Symptomatic distal sensory polyneuropathy in HIV after age 50
Watters, M. R., Poff, P., Shiramizu, B. T., Holck, P. S., Fast, K. M. S., Shikuma, C. M., & Valcour, V. (2004) · Neurology · doi:10.1212/01.wnl.0000120622.91018.ea · Cited by 51 · see citing works
Self-citationPD-1 induction through TCR activation is partially regulated by endogenous TGF-β
Rekik, R., Hmida, N. B., Hmid, A. B., Zamali, I., Kammoun, N., & Ahmed, M. B. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.104 · Cited by 45 · see citing works
Sun, Y., Schmitz, J. E., Acierno, P. M., Santra, S., Subbramanian, R. A., Barouch, D. H., Gorgone, D. A., Lifton, M. A., Beaudry, K. R., Manson, K. H., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4753 · Cited by 30 · see citing works
Fujita, T., Burwitz, B. J., Chew, G. M., Reed, J. S., Pathak, R., Seger, E., Clayton, K., Rini, J. M., Ostrowski, M., Ishii, N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400961 · Cited by 30 · see citing works
Self-citationBarbour, J. D., Ndhlovu, L. C., Tan, Q. X., Ho, T. N., Epling, L., Bredt, B. M., Levy, J. A., Hecht, F. M., & Sinclair, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004408 · Cited by 27 · see citing works
Self-citationLópez, M., Soriano, V., Peris-Pertusa, A., Rallón, N. I., Restrepo, C., & Benito, J. M. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0107 · Cited by 27 · see citing works
CD8+ Memory T Cells Appear Exhausted within Hours of Acute Virus Infection
Hosking, M., Flynn, C. T., Botten, J., & Whitton, J. L. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300920 · Cited by 22 · see citing works
Foks, A. C., Ran, I. A., Frodermann, V., Bot, I., van Santbrink, P. J., Kuiper, J., & van Puijvelde, G. H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083134 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works
Immune checkpoint blockade in infectious diseases
Wykes, M., & Lewin, S. R. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.112 · Cited by 569 · see citing works
TIGIT as an emerging immune checkpoint
Harjunpää, H., & Guillerey, C. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13407 · Cited by 552 · see citing works
Immune checkpoints and their inhibition in cancer and infectious diseases
Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541 · see citing works
CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
Fromentin, R., Bakeman, W., Lawani, M. B., Khoury, G., Hartogensis, W., DaFonseca, S., Killian, M. L., Epling, L., Hoh, R., Sinclair, E., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005761 · Cited by 418 · see citing works
Self-citationGetting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV
Kim, Y., Anderson, J. L., & Lewin, S. R. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.004 · Cited by 412 · see citing works
T‐cell exhaustion in HIV infection
Fenwick, C. W., Joo, V., Jacquier, P., Noto, A., Banga, R., Perreau, M., & Pantaleo, G. (2019) · Immunological Reviews · doi:10.1111/imr.12823 · Cited by 412 · see citing works
Rotte, A., Jin, J., & Lemaire, V. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 346 · see citing works
Ghosn, J., Taiwo, B., Seedat, S., Autran, B., & Katlama, C. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31311-4 · Cited by 306 · see citing works
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies
Cohn, L. B., Chomont, N., & Deeks, S. G. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.014 · Cited by 280 · see citing works
Self-citationT cell senescence and CAR-T cell exhaustion in hematological malignancies
Kasakovski, D., Xu, L., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0629-x · Cited by 274 · see citing works
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease
Attanasio, J., & Wherry, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.022 · Cited by 256 · see citing works
IL-15 in the Combination Immunotherapy of Cancer
Waldmann, T. A., Dubois, S. P., Miljković, M. D., & Conlon, K. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00868 · Cited by 249 · see citing works
Cunha, L. L., Perazzio, S. F., Azzi, J., Cravedi, P., & Riella, L. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01748 · Cited by 239 · see citing works
Latency reversal and viral clearance to cure HIV-1
Margolis, D. M., García, J. V., Hazuda, D. J., & Haynes, B. F. (2016) · Science · doi:10.1126/science.aaf6517 · Cited by 236 · see citing works
Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy
Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W. L., & Smyth, M. J. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0933 · Cited by 223 · see citing works
Fromentin, R., DaFonseca, S., Costiniuk, C. T., Far, M. E., Procopio, F. A., Hecht, F. M., Hoh, R., Deeks, S. G., Hazuda, D. J., Lewin, S. R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08798-7 · Cited by 207 · see citing works
Self-citationAntigen Availability Shapes T Cell Differentiation and Function during Tuberculosis
Moguche, A. O., Musvosvi, M., Penn‐Nicholson, A., Plumlee, C. R., Mearns, H., Geldenhuys, H. D., Smit, E., Abrahams, D. A., Rozot, V., Dintwe, O., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.05.012 · Cited by 172 · see citing works
Avery, L., Filderman, J. N., Szymczak-Workman, A. L., & Kane, L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712107115 · Cited by 166 · see citing works
Why and where an HIV cure is needed and how it might be achieved
Ndung’u, T., McCune, J. M., & Deeks, S. G. (2019) · Nature · doi:10.1038/s41586-019-1841-8 · Cited by 144 · see citing works
Self-citationJoller, N., & Kuchroo, V. K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_62 · Cited by 138 · see citing works
Recommendations for measuring HIV reservoir size in cure-directed clinical trials
Abdel‐Mohsen, M., Richman, D. D., Siliciano, R. F., Nussenzweig, M. C., Howell, B. J., Martínez‐Picado, J., Chomont, N., Bar, K. J., Yu, X. G., Lichterfeld, M. D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1022-1 · Cited by 132 · see citing works
Self-citationBarriers and strategies to achieve a cure for HIV
Pitman, M. C., Lau, J. S. Y., McMahon, J. H., & Lewin, S. R. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(18)30039-0 · Cited by 124 · see citing works
Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
Naran, K., Nundalall, T., Chetty, S., & Barth, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03158 · Cited by 123 · see citing works
Transcriptome Profiling Identifies TIGIT as a Marker of T‐Cell Exhaustion in Liver Cancer
Ostroumov, D., Duong, S., Wingerath, J., Woller, N., Manns, M. P., Timrott, K., Kleine, M., Ramackers, W., Roessler, S. K., Nahnsen, S., et al. (2020) · Hepatology · doi:10.1002/hep.31466 · Cited by 117 · see citing works
Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection
Mu, W., Patankar, V., Kitchen, S. G., & Zhen, A. (2024) · Viruses · doi:10.3390/v16020219 · Cited by 108 · see citing works
T‐cell Immunoglobulin and ITIM Domain Contributes to CD 8+ T‐cell Immunosenescence
Song, Y., Wang, B., Song, R., Yu, H., Wang, D., Li, Y., Jiang, Y. Y., Xu, L., Ma, Y., Zheng, H., et al. (2018) · Aging Cell · doi:10.1111/acel.12716 · Cited by 105 · see citing works
Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 104 · see citing works
Wang, S., Zhang, Q., Hui, H., Agrawal, K., Karris, M., & Rana, T. M. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1826361 · Cited by 99 · see citing works
Engaging innate immunity in HIV-1 cure strategies
Nathan L. Board, Moskovljevic, M., Wu, F., Siliciano, R. F., & Siliciano, J. D. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00649-1 · Cited by 98 · see citing works
The multifaceted nature of HIV latency
Dufour, C., Gantner, P., Fromentin, R., & Chomont, N. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136227 · Cited by 94 · see citing works
TCF-1 regulates HIV-specific CD8+ T cell expansion capacity
Rutishauser, R. L., Deguit, C. D. T., Hiatt, J. B., Blaeschke, F., Roth, T. L., Wang, L., Raymond, K. A., Starke, C. E., Mudd, J. C., Chen, W., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136648 · Cited by 93 · see citing works
Self-citationImmunological approaches to HIV cure
Ward, A. R., Mota, T. M., & Jones, R. B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101412 · Cited by 92 · see citing works
Clarridge, K. E., Blažková, J., Einkauf, K. B., Petrone, M. E., Refsland, E. W., Justement, J. S., Shi, V., Huiting, E. D., Seamon, C. A., Lee, G. Q., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006792 · Cited by 90 · see citing works
Jackson, Z., Hong, C., Schauner, R., Dropulić, B., Caimi, P. F., Lima, M. J. G. D., Giraudo, M. F., Gupta, K., Reese, J., Hwang, T. H., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1586 · Cited by 85 · see citing works
Zhang, C., Lin, R., Li, L., Yang, S., Bi, X., Wang, H., Aini, A., Zhang, N., Abulizi, A., Sun, C., et al. (2019) · Hepatology · doi:10.1002/hep.30896 · Cited by 84 · see citing works
Wang, M., Bu, J., Zhou, M., Sido, J. M., Lin, Y., Liu, G., Lin, Q., Xu, X., Leavenworth, J. W., & Shen, E. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.021 · Cited by 83 · see citing works
Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice
Zong, L., Peng, H. C., Sun, C., Li, F., Zheng, M., Chen, Y., Wei, H., Sun, R., & Tian, Z. (2019) · Nature Communications · doi:10.1038/s41467-018-08096-8 · Cited by 81 · see citing works
T-cell exhaustion correlates with improved outcomes in kidney transplant recipients
Fribourg, M., Anderson, L., Fischman, C. J., Cantarelli, C., Perin, L., Manna, G. L., Rahman, A. H., Burrell, B. E., Heeger, P. S., & Cravedi, P. (2019) · Kidney International · doi:10.1016/j.kint.2019.01.040 · Cited by 81 · see citing works
Immune Aging and Immunotherapy in Cancer
Kaiser, M., Semeraro, M. D., Herrmann, M., Absenger, G., Gerger, A., & Renner, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137016 · Cited by 78 · see citing works
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
Rotte, A., Sahasranaman, S., & Budha, N. R. (2021) · Biomedicines · doi:10.3390/biomedicines9091277 · Cited by 77 · see citing works
Advances toward Curing HIV-1 Infection in Tissue Reservoirs
Henderson, L. J., Reoma, L. B., Kovacs, J. A., & Nath, A. (2019) · Journal of Virology · doi:10.1128/jvi.00375-19 · Cited by 76 · see citing works
TIGIT limits immune pathology during viral infections
Schorer, M., Rakebrandt, N., Lambert, K., Hunziker, A., Pallmer, K., Oxenius, A., Kipar, A., Stertz, S., & Joller, N. (2020) · Nature Communications · doi:10.1038/s41467-020-15025-1 · Cited by 76 · see citing works
Stecher, C., Battin, C., Leitner, J. M., Zettl, M., Grabmeier‐Pfistershammer, K., Höeller, C., Zlabinger, G. J., & Steinberger, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00572 · Cited by 72 · see citing works
Galectin-9 and VISTA Expression Define Terminally Exhausted T Cells in HIV-1 Infection
Shahbaz, S., Dunsmore, G., Koleva, P. T., Xu, L., Houston, S. C., & Elahi, S. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901481 · Cited by 72 · see citing works
Tauriainen, J., Scharf, L., Frederiksen, J., Naji, A., Ljunggren, H., Sönnerborg, A. B., Lund, O., Reyes‐Terán, G., Hecht, F. M., Deeks, S. G., et al. (2017) · Scientific Reports · doi:10.1038/srep40354 · Cited by 71 · see citing works
Self-citationImmune checkpoint blockade in HIV
Gubser, C., Chiu, C. Y. H., Lewin, S. R., & Rasmussen, T. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103840 · Cited by 69 · see citing works
Between a shock and a hard place: challenges and developments in HIV latency reversal
Zerbato, J. M., Purves, H. V., Lewin, S. R., & Rasmussen, T. A. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.03.004 · Cited by 68 · see citing works
Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies
Bhandaru, M., & Rotte, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_4 · Cited by 67 · see citing works
Preillon, J., Cuende, J., Rabolli, V., Garnero, L., Mercier, M., Wald, N., Pappalardo, A., Denies, S., Jamart, D., Michaux, A.-C., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0464 · Cited by 66 · see citing works
The multifaceted nature of HIV latency
Dufour, C., Gantner, P., Fromentin, R., & Chomont, N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151380 · Cited by 63 · see citing works
Gao, X., Li, W., Syed, F., Yuan, F., Li, P., & Yu, Q. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02398-x · Cited by 62 · see citing works
TIGIT signalling pathway negatively regulates CD 4+ T‐cell responses in systemic lupus erythematosus
Mao, L., Hou, H., Wu, S., Zhou, Y., Wang, J., Yu, J., Wu, X., Lu, Y., Mao, L., Munyemana, J. B., et al. (2017) · Immunology · doi:10.1111/imm.12715 · Cited by 62 · see citing works
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
Ottaviano, M., Placido, S. D., & Ascierto, P. A. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02538-4 · Cited by 62 · see citing works
Srivastava, R., Hernández-Ruíz, M., Khan, A. A., Fouladi, M. A., Kim, G. J., Ly, V. T., Yamada, T., Lam, C., Sarain, S. A. B., Boldbaatar, U., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701474 · Cited by 60 · see citing works
Yin, X., Liu, T., Wang, Z., Ma, M., Lei, J., Zhang, Z., Fu, S., Fu, Y., Hu, Q., Ding, H., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02341 · Cited by 59 · see citing works
Vendrame, E., Seiler, C., Ranganath, T., Zhao, N. Q., Vergara, R., Alary, M., Labbé, A., Guédou, F. A., Poudrier, J., Holmes, S., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002488 · Cited by 57 · see citing works
TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer
Xu, D., Zhao, E., Zhu, C., Zhao, W., Wang, C., Zhang, Z., & Zhao, G. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.151915 · Cited by 57 · see citing works
The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like
Darcis, G., Berkhout, B., & Pasternak, A. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02251 · Cited by 56 · see citing works
Immune Checkpoints in Viral Infections
Cai, H., Liu, G., Zhong, J., Zheng, K., Xiao, H., Li, C., Song, X., Li, Y., Xu, C., Wu, H., et al. (2020) · Viruses · doi:10.3390/v12091051 · Cited by 54 · see citing works
Self-citationSrivastava, R., Khan, A. A., Chilukuri, S., Syed, S. A., Tran, T. T., Furness, J. N., Bahraoui, E., & BenMohamed, L. (2017) · Journal of Virology · doi:10.1128/jvi.00278-17 · Cited by 53 · see citing works
LAG3 (CD223) and autoimmunity: Emerging evidence
Hu, S., Liu, X., Li, T., Li, Z., & Hu, F. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102504 · Cited by 53 · see citing works
Shive, C. L., Freeman, M. L., Younes, S., Kowal, C. M., Canaday, D. H., Rodriguez, B. A., Lederman, M. M., & Anthony, D. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638010 · Cited by 51 · see citing works
Is There a Positive Side to T Cell Exhaustion?
Pawelec, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00111 · Cited by 50 · see citing works
Ackermann, C., Smits, M., Woost, R., Eberhard, J. M., Peine, S., Kummer, S., Marget, M., Kuntzen, T., Kwok, W. W., Lohse, A. W., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-47024-8 · Cited by 49 · see citing works
Vadrevu, S. K., Trbojević‐Akmačić, I., Kossenkov, A. V., Colomb, F., Giron, L. B., Anzurez, A., Lynn, K., Mounzer, K., LANDAY, A. L., Kaplan, R. C., et al. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3hi1217-500r · Cited by 48 · see citing works
Self-citationBispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Nathan L. Board, Yuan, Z., Wu, F., Moskovljevic, M., Ravi, M., Sengupta, S., Mun, S. S., Simonetti, F. R., Lai, J., Tebas, P., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01741-5 · Cited by 46 · see citing works
Self-citationThe Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer
Carrillo, M. A., Zhen, A., & Kitchen, S. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00746 · Cited by 46 · see citing works
Horsburgh, B. A., Lee, E., Hiener, B. M., Eden, J., Schlub, T. E., von Stockenström, S., Odevall, L., Milush, J. M., Liegler, T. J., Sinclair, E., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002465 · Cited by 46 · see citing works
Self-citationCD32-Expressing CD4 T Cells Are Phenotypically Diverse and Can Contain Proviral HIV DNA
Martin, G. E., Pace, M. J., Thornhill, J. P., Phetsouphanh, C., Meyerowitz, J., Gossez, M., Hopkins, E., Brown, H., Robinson, N., Olejniczak, N. J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00928 · Cited by 44 · see citing works
RNA Therapeutics for Improving CAR T-cell Safety and Efficacy
Schaible, P., Bethge, W. A., Lengerke, C., & Haraszti, R. Á. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2155 · Cited by 43 · see citing works
Hazrati, A., Malekpour, K., Khorramdelazad, H., Rajaei, S., & Hashemi, S. M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00580-2 · Cited by 43 · see citing works
Sugar or Fat?—Metabolic Requirements for Immunity to Viral Infections
Shehata, H. M., Murphy, A. J., Lee, M. K. S., Gardiner, C. M., Crowe, S. M., Sanjabi, S., Finlay, D. K., & Palmer, C. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01311 · Cited by 43 · see citing works
Check point inhibitors as therapies for infectious diseases
Cox, M. A., Nechanitzky, R., & Mak, T. W. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.016 · Cited by 42 · see citing works
Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects
Hu, Y., Tian, Z., & Zhang, C. (2018) · Engineering · doi:10.1016/j.eng.2018.11.015 · Cited by 42 · see citing works
Corneau, A., Cosma, A., Even, S., Katlama, C., Grand, R. L., Martel‐Frachet, V., Blanc, C., & Autran, B. (2016) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21502 · Cited by 40 · see citing works
Zhang, X., Zhang, H., Chen, L., Feng, Z., Gao, L., & Li, Q. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103958 · Cited by 39 · see citing works
Belkina, A. C., Starchenko, A., Drake, K., Proctor, E. A., Pihl, R. M. F., Olson, A., Lauffenburger, D. A., Lin, N., & Snyder-Cappione, J. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02783 · Cited by 38 · see citing works
Emergence of the CD226 Axis in Cancer Immunotherapy
Conner, M., Hance, K. W., Yadavilli, S., Smothers, J. F., & Waight, J. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914406 · Cited by 38 · see citing works
Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies
Castelli, V., Lombardi, A., Palomba, E., Bozzi, G., Ungaro, R., Alagna, L., Mangioni, D., Muscatello, A., Bandera, A., & Gori, A. (2021) · Cells · doi:10.3390/cells10092227 · Cited by 37 · see citing works
Rasmussen, T. A., Zerbato, J. M., Rhodes, A., Tumpach, C., Dantanarayana, A., McMahon, J. H., Lau, J. S. Y., Chang, J. J., Gubser, C., Brown, W., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100766 · Cited by 37 · see citing works
Self-citationAlrubayyi, A., Cubero, E. M., Hameiri‐Bowen, D., Matthews, R., Rowland‐Jones, S., Schurich, A., & Peppa, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908697 · Cited by 36 · see citing works
The latest evidence for possible HIV-1 curative strategies
Pham, H. T., & Mésplède, T. (2018) · Drugs in Context · doi:10.7573/dic.212522 · Cited by 36 · see citing works
Strongin, Z., Marchand, L. R., Deléage, C., Pampena, M. B., Cardenas, M. A., Beusch, C. M., Hoang, T. N., Urban, E., Gourvès, M., Nguyen, K., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01875-0 · Cited by 35 · see citing works
Immune checkpoint inhibitors in infectious disease
King, H. A. D., & Lewin, S. R. (2024) · Immunological Reviews · doi:10.1111/imr.13388 · Cited by 35 · see citing works
Jantz-Naeem, N., Loschinski, R., Borucki, K., Mitchell-Flack, M., Böttcher, M., Schraven, B. L., Mougiakakos, D., & Kahlfuß, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1060112 · Cited by 35 · see citing works
Benito, J. M., Restrepo, C., García‐Foncillas, J., & Rallón, N. I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270881 · Cited by 33 · see citing works
Shikuma, C. M., Chew, G. M., Kohorn, L. B., Souza, S. A., Chow, D. C., SahBandar, I. N., Park, E. Y., Hanks, N., Gangcuangco, L. M. A., Gerschenson, M., et al. (2019) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2019.0078 · Cited by 33 · see citing works
Self-citationHIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 + T Cells
Prévost, J., Edgar, C. R., Richard, J., Trothen, S. M., Jacob, R. A., Mumby, M. J., Pickering, S., Dubé, M., Kaufmann, D., Kirchhoff, F., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01999-19 · Cited by 33 · see citing works
The CD8 + T Cell Noncytotoxic Antiviral Responses
Morvan, M. G., Teque, F., Locher, C. P., & Levy, J. A. (2021) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00155-20 · Cited by 33 · see citing works
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33 · see citing works
Teigler, J. E., Zelinskyy, G., Eller, M. A., Bolton, D. L., Marovich, M., Gordon, A. D., Alrubayyi, A., Alter, G., Robb, M. L., Martin, J. N., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01263-17 · Cited by 32 · see citing works
Self-citationChiu, C. Y. H., Chang, J. J., Dantanarayana, A., Solomon, A. E., Evans, V. A., Pascoe, R. D., Gubser, C., Trautmann, L., Fromentin, R., Chomont, N., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100367 · Cited by 31 · see citing works
Impact of Myeloid Reservoirs in HIV Cure Trials
Mitchell, B. I., Laws, E. I., & Ndhlovu, L. C. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00438-5 · Cited by 31 · see citing works
Self-citationCAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
Kim, G. B., Hege, K. M., & Riley, J. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02310 · Cited by 30 · see citing works
Pino, M., Ribeiro, S. P., Pagliuzza, A., Ghneim, K., Khan, A. N., Ryan, E. S., Harper, J. L., King, C. T., Welbourn, S., Micci, L., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009825 · Cited by 30 · see citing works
Noyan, K., Nguyen, S., Betts, M. R., Sönnerborg, A. B., & Buggert, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00019 · Cited by 30 · see citing works
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy
Martin, G. E., Sen, D. R., Pace, M. J., Robinson, N., Meyerowitz, J., Adland, E., Thornhill, J. P., Jones, M., Ogbe, A., Parolini, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647688 · Cited by 29 · see citing works
Chaudhary, O., Trotta, D., Wang, K., Wang, X., Chu, X., Bradley, C., Okulicz, J. F., Maves, R. C., Kronmann, K., Schofield, C. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004564 · Cited by 28 · see citing works
Hashemi, P., & Sadowski, I. (2019) · Medicinal Research Reviews · doi:10.1002/med.21638 · Cited by 27 · see citing works
- Authors
- Chew, G. M., Fujita, T., Webb, G. M., Burwitz, B. J., Wu, H. L., Reed, J. S., Hammond, K. B., Clayton, K. L., Ishii, N., Abdel-Mohsen, M., Liegler, T., Mitchell, B. I., Hecht, F. M., Ostrowski, M., Shikuma, C. M., Hansen, S. G., Maurer, M., Korman, A. J., Deeks, S. G., Sacha, J. B., & Ndhlovu, L. C.
- Affiliations
- University of Hawaiʻi at Mānoa (US)
- Oregon National Primate Research Center (US)
- University of Toronto (CA)
- Tohoku University (JP)
- San Francisco General Hospital (US)
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Ndhlovu, Lishomwa C.
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-01-07
- Volume
- 12
- Issue
- 1
- Pages
- e1005349
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC4704737
- OpenAlex
- W2225639217
- Cited by
- 323
- References
- 63
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 30 · 2023: 33 · 2022: 33 · 2021: 47 · 2020: 44 · 2019: 36 · 2018: 32 · 2017: 18 · 2016: 12
- FWCI
- 22.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Bristol-Myers Squibb
- Oregon Health and Science University (OD011092)
- International AIDS Society
- National Institutes of Health (n01ai085341-004, OD-011092, RR024131, AI027763, NOI-AI-85341, P51OD011092)
- University of California, San Francisco (P30AI027763, UL1RR024131)
- Japan Society for the Promotion of Science (15H04742)
- National Institute of General Medical Sciences (P30GM103341)
- National Institute of Allergy and Infectious Diseases (N01 AI085341, K24AI069994, OD011092, RO1 AI087145, AI027763, RR024131, AI067039, AI069994, AI087145, NOI-AI-85341, HIV-1, R01AI087145, N0I-AI-85341, R24AI067039, P30AI027763)
- National Center for Research Resources (UL1RR024131, RR 024131)
- Office of AIDS Research
- National Institute on Minority Health and Health Disparities (U54MD007584)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- TIGIT, T cell exhaustion, HIV infection, SIV infection, CD8+ T cells, PD-1, PD-L1, immune checkpoint receptors, disease progression, elite controllers, viral suppression, T cell dysfunction, immune restoration, antibody blocking
- MeSH terms
- Animals, Cell Separation, DNA, Viral, Flow Cytometry, Humans, Lymphocyte Activation, Macaca mulatta, Receptors, Immunologic, RNA, Viral, CD4-Positive T-Lymphocytes, HIV Infections, Simian Acquired Immunodeficiency Syndrome, CD8-Positive T-Lymphocytes, Disease Progression, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
